Form 4: Fennec Pharmaceuticals Director Rosty Raykov Reports Share Sale
SEC Form 4
Director Rosty Raykov of Fennec Pharmaceuticals reports the sale of 2,431 common shares at $4.31 per share, alongside the release of restrictions on 2,431 previously awarded shares.
Summary
- Rosty Raykov, a director of Fennec Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
- On October 31, 2024, restrictions were released on 2,431 common shares previously awarded to Raykov.
- On November 4, 2024, Raykov sold 2,431 common shares at a price of $4.31 per share.
- Following these transactions, Raykov beneficially owns 66,432 common shares.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing a share sale by a company director. It doesn't inherently convey positive or negative sentiment, as it's simply a report of transactions.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. The use of a 10b5-1 plan suggests the sale was pre-planned to avoid accusations of insider trading.
Stakeholder Impact
- The share sale by a director could have a minor impact on shareholder sentiment, but the use of a 10b5-1 plan mitigates concerns about insider trading.
Key Dates
| Date | Description |
|---|---|
| 2023-12-14 | Date of 10b5-1 plan adoption |
| 2023-03-31 | Date shares were awarded |
| 2024-10-31 | Release of restriction from shares awarded |
| 2024-11-04 | Date of share sale |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.